Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0090133
Title: Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery
Authors: Lee, J.
Sohn, I.
Do, I.-G.
Kim, K.-M.
Park, S.H.
Park, J.O.
Park, Y.S.
Lim, H.Y.
Sohn, T.S.
Bae, J.M.
Choi, M.G.
Lim, D.H.
Min, B.H.
Lee, J.H.
Rhee, P.L.
Kim, J.J.
Choi, D.I.
Tan, I.B.
Das, K.
Tan, P. 
Jung, S.H.
Kang, W.K.
Kim, S.
Issue Date: 5-Mar-2014
Citation: Lee, J., Sohn, I., Do, I.-G., Kim, K.-M., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Sohn, T.S., Bae, J.M., Choi, M.G., Lim, D.H., Min, B.H., Lee, J.H., Rhee, P.L., Kim, J.J., Choi, D.I., Tan, I.B., Das, K., Tan, P., Jung, S.H., Kang, W.K., Kim, S. (2014-03-05). Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS ONE 9 (3) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0090133
Abstract: Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N = 432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N = 186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N = 216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N = 300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N = 216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence = 3.16, p = 0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio = 1.77, p = 0.0053). © 2014 Lee et al.
Source Title: PLoS ONE
URI: http://scholarbank.nus.edu.sg/handle/10635/110590
ISSN: 19326203
DOI: 10.1371/journal.pone.0090133
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2014-nanostring-based_multigene_assay_predict_recurrence-published.pdf487.18 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

68
checked on Jun 13, 2021

WEB OF SCIENCETM
Citations

69
checked on Jun 4, 2021

Page view(s)

273
checked on Jun 7, 2021

Download(s)

4
checked on Jun 7, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.